Iterum Therapeutics (ITRM) & Its Peers Critical Survey

Iterum Therapeutics (NASDAQ: ITRM) is one of 546 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Iterum Therapeutics to similar businesses based on the strength of its risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Iterum Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iterum Therapeutics 0 0 5 0 3.00
Iterum Therapeutics Competitors 4499 12939 27592 991 2.54

Iterum Therapeutics presently has a consensus target price of $20.75, indicating a potential upside of 142.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 52.41%. Given Iterum Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than its rivals.

Valuation and Earnings

This table compares Iterum Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Iterum Therapeutics $870,000.00 -$77.06 million -1.20
Iterum Therapeutics Competitors $2.17 billion $229.91 million -3.77

Iterum Therapeutics’ rivals have higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

45.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Iterum Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iterum Therapeutics N/A N/A N/A
Iterum Therapeutics Competitors -1,776.08% -105.48% -28.48%

Summary

Iterum Therapeutics beats its rivals on 7 of the 12 factors compared.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.